MedTrace Logo

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

NCT00477087 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-11-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effect of the combination of mitoxantrone and granulocyte-macrophage colony stimulating factor (GM-CSF) on progression-free survival (PFS) and overall survival (OS), in patients with hormone-refractory prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Mitoxantrone

Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.

DRUG

GM-CSF

GM-CSF is a biologic response modifier, classified as a colony stimulating factor.

Sponsors & Collaborators

Principal Investigators

  • Dr. Sandy Srinivas · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2009-10-31
Completion
2010-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00477087 on ClinicalTrials.gov